糖尿病心血管结局试验的结果。 - Suppr

Results from Cardiovascular Outcome Trials in Diabetes.

作者信息

Muñoz Torres Manuel, Muñoz Garach Araceli

机构信息

UGC Endocrinología y Nutrición, Hospital Universitario San Cecilio, Complejo Hospitalario Universitario de Granada, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, España.

UGC Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España.

出版信息

Endocrinol Nutr. 2016 Aug-Sep;63(7):317-9. doi: 10.1016/j.endonu.2016.04.001. Epub 2016 Jun 17.

DOI:10.1016/j.endonu.2016.04.001

PMID:27324936

Abstract

摘要

相似文献

Results from Cardiovascular Outcome Trials in Diabetes.

Endocrinol Nutr. 2016 Aug-Sep;63(7):317-9. doi: 10.1016/j.endonu.2016.04.001. Epub 2016 Jun 17.

New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.

Rev Esp Cardiol (Engl Ed). 2016 Nov;69(11):1005-1007. doi: 10.1016/j.rec.2016.07.009. Epub 2016 Sep 19.

Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.

Can J Ophthalmol. 2017 Nov;52 Suppl 1:S4-S7. doi: 10.1016/j.jcjo.2017.07.028. Epub 2017 Oct 4.

[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].

Rev Med Suisse. 2016 Aug 24;12(527):1370-1375.

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):435-437. doi: 10.1016/S2213-8587(17)30314-5. Epub 2017 Oct 10.

[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].

Praxis (Bern 1994). 2016 Mar 16;105(6):349-50. doi: 10.1024/1661-8157/a002288.

Updates on cardiovascular outcome trials in diabetes.

Cardiovasc Diabetol. 2017 Oct 11;16(1):128. doi: 10.1186/s12933-017-0610-y.

[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].

Dtsch Med Wochenschr. 2016 Jun;141(11):757-60. doi: 10.1055/s-0042-107747. Epub 2016 May 13.

Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians.

Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25.

Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.

Clin Ther. 2016 Jun;38(6):1279-1287. doi: 10.1016/j.clinthera.2016.03.035. Epub 2016 Apr 20.

引用本文的文献

Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis.

Nutrients. 2021 Oct 12;13(10):3568. doi: 10.3390/nu13103568.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Results from Cardiovascular Outcome Trials in Diabetes.

作者信息

Muñoz Torres Manuel, Muñoz Garach Araceli

机构信息

UGC Endocrinología y Nutrición, Hospital Universitario San Cecilio, Complejo Hospitalario Universitario de Granada, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, España.

UGC Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España.

出版信息

Endocrinol Nutr. 2016 Aug-Sep;63(7):317-9. doi: 10.1016/j.endonu.2016.04.001. Epub 2016 Jun 17.

DOI:10.1016/j.endonu.2016.04.001

PMID:27324936

Abstract

摘要

相似文献

Results from Cardiovascular Outcome Trials in Diabetes.

Endocrinol Nutr. 2016 Aug-Sep;63(7):317-9. doi: 10.1016/j.endonu.2016.04.001. Epub 2016 Jun 17.

New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.

Rev Esp Cardiol (Engl Ed). 2016 Nov;69(11):1005-1007. doi: 10.1016/j.rec.2016.07.009. Epub 2016 Sep 19.

Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.

Can J Ophthalmol. 2017 Nov;52 Suppl 1:S4-S7. doi: 10.1016/j.jcjo.2017.07.028. Epub 2017 Oct 4.

[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].

Rev Med Suisse. 2016 Aug 24;12(527):1370-1375.

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):435-437. doi: 10.1016/S2213-8587(17)30314-5. Epub 2017 Oct 10.

[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].

Praxis (Bern 1994). 2016 Mar 16;105(6):349-50. doi: 10.1024/1661-8157/a002288.

Updates on cardiovascular outcome trials in diabetes.

Cardiovasc Diabetol. 2017 Oct 11;16(1):128. doi: 10.1186/s12933-017-0610-y.

[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].

Dtsch Med Wochenschr. 2016 Jun;141(11):757-60. doi: 10.1055/s-0042-107747. Epub 2016 May 13.

Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians.

Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25.

Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.

Clin Ther. 2016 Jun;38(6):1279-1287. doi: 10.1016/j.clinthera.2016.03.035. Epub 2016 Apr 20.

引用本文的文献

Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis.

Nutrients. 2021 Oct 12;13(10):3568. doi: 10.3390/nu13103568.

Results from Cardiovascular Outcome Trials in Diabetes.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Results from Cardiovascular Outcome Trials in Diabetes.

作者信息

机构信息

出版信息

相似文献

引用本文的文献